Any feedback?
Literature summary extracted from
- Alfimeprase (2008), Drugs R. D., 9, 185-190.
Application
| EC Number | Application | Comment | Organism |
|---|---|---|---|
| 3.4.24.72 | drug development | summary of results (including adverse events and pharmacodynamics) regarding drug development of alfimeprase as a potential drug against thrombosis and vascular disorders | Agkistrodon contortrix contortrix |
Cloned(Commentary)
| EC Number | Cloned (Comment) | Organism |
|---|---|---|
| 3.4.24.72 | production of alfimeprase by recombinant DNA technology | Agkistrodon contortrix contortrix |
Organism
| EC Number | Organism | UniProt | Comment | Textmining |
|---|---|---|---|---|
| 3.4.24.72 | Agkistrodon contortrix contortrix | - |
- |
- |
Specific Activity [micromol/min/mg]
| EC Number | Specific Activity Minimum [µmol/min/mg] | Specific Activity Maximum [µmol/min/mg] | Comment | Organism |
|---|---|---|---|---|
| 3.4.24.72 | additional information | - |
thrombolytic activity | Agkistrodon contortrix contortrix |
Synonyms
| EC Number | Synonyms | Comment | Organism |
|---|---|---|---|
| 3.4.24.72 | 3-203-fibrolase[3-serine] | - |
Agkistrodon contortrix contortrix |
| 3.4.24.72 | Alfimeprase | - |
Agkistrodon contortrix contortrix |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
